Waander L. van Heerde

Biochemist, Coagulation Physiologist, Chief Scientific Officer Enzyre BV
Department of Hematology, Radboud university medical center, Nijmegen, The Netherlands. Hemophilia Treatment Center Nijmegen – Eindhoven – Maastricht, The Netherlands. Enzyre BV, Novio Tech Campus, Nijmegen, The Netherlands.

Presentation(s):

• PB0563 - The ultra-sensitive Nijmegen Inhibitor Assay detects very low-titer factor VIII inhibitors.

  Monday, July 11, 2022
  6:30 PM – 7:30 PM

• OC 63.1 - Decreased thrombin generation profile is associated with severe bleeding phenotype in hemophilia: data from the Hemophilia in the Netherlands study

  Tuesday, July 12, 2022
  2:45 PM – 3:00 PM

• PB1179 - Efficacy of subcutaneous versus intravenous administration of desmopressin in patients with von Willebrand disease and hemophilia A in need of COVID-19 vaccination

  Tuesday, July 12, 2022
  6:30 PM – 7:30 PM

• OC 78.2 - Whole exome sequencing in patients with rare bleeding disorders: data from the RBiN study

  Wednesday, July 13, 2022
  10:30 AM – 10:45 AM